Covid vaccination for under 15 only after scientific data evolves: Centre

The Covid vaccination drive for the 12 to 14 years age group will start only after more scientific data evolves, Union Health Secretary Rajesh Bhushan said

vaccine
IANS New Delhi
2 min read Last Updated : Jan 21 2022 | 8:40 AM IST

The Covid vaccination drive for the 12 to 14 years age group will start only after more scientific data evolves, Union Health Secretary Rajesh Bhushan said on Thursday.

"As scientific evidence evolves, we will be expanding the coverage of vaccination to this age group. We will take decision on the basis of scientific data in this regard," he said while addressing the media on the current Covid surge in India.

NITI Aayog's Member, Health, Dr V.K. Paul said that vaccinating this age bracket is an important objective. "We will take decision on this when we will have compete scientific evidence," he said.

About the Subject Expert Committee of the Central Drug Standard and Control Organisation (CDSCO) recommendation to provide market approval for two vaccines Covishield and Covaxin, Bhushan said that the recommendation has been made to the national regulator, the Drug Controller General of India, but, it is yet to take the final decision.

He said that of the frontline workers who were due for their precautionary dose, 58 per cent of them have received it, and of the healthcare workers who were due, 63 per cent of them have received the vaccine as on January 20. "Out of total around 80 lakh due for precaution dose among 60 plus age group as on January 20, total 18,66,000 have received their dose which is around 39 per cent," he added.

Bhushan also said that 52 per cent children in 15-18 age group in the country have been vaccinated so far.

On active cases, he said Maharashtra, Karnataka, Tamil Nadu, Kerala, West Bengal, UP, Gujarat, Odisha, Delhi, and Rajasthan are among the top 10 states, and of them, Maharashtra, Karnataka, Tamil Nadu, Kerala, Delhi and Uttar Pradesh are among the 'States of Concern' and the situation is being reviewed continuously.

--IANS

avr/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccinegovernment of India

First Published: Jan 21 2022 | 8:40 AM IST

Next Story